<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637700</url>
  </required_header>
  <id_info>
    <org_study_id>IVIg-SFN</org_study_id>
    <secondary_id>2015-002624-31</secondary_id>
    <nct_id>NCT02637700</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy</brief_title>
  <acronym>IVIg-SFN</acronym>
  <official_title>Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Ziekenhuis Maastricht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Small fiber neuropathy (SFN) is the most common cause of neuropathic pain in peripheral
      neuropathies, with a prevalence of at least 53/100.000. Patients with SFN may have
      excruciating pain and current anti-neuropathic and other pain drugs do not relief pain
      substantially.

      Several studies suggested an immunological basis in SFN and case studies have reported
      efficacy of treatment with intravenous immunoglobulin (IVIg) in patients with SFN. It is
      therefore conceivable that immunological mechanisms play a role in idiopathic SFN (I-SFN).
      However, to date no randomized controlled study with IVIg in patients with SFN has been
      performed. The aim of the current study is to investigate the efficacy and safety of IVIg in
      patients with I-SFN in a randomized, double-blind, placebo-controlled study.

      The objective of the study is to evaluate the efficacy of IVIg treatment (4 courses of
      treatment, 3 weeks apart) compared to placebo on pain alleviation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Small nerve fiber neuropathy (SFN) is a disorder of thinly myelinated and unmyelinated nerve
      fibers recently recognized as a distinct clinical syndrome, with a minimum incidence of 12
      per 100.000 and a minimum prevalence of 53 per 100.000. The clinical picture is typically
      dominated by neuropathic pain, often with a burning quality, and autonomic symptoms. The
      diagnosis of SFN is usually made on the basis of the clinical picture, no involvement of
      large nerve fibers at neurological examination and normal nerve conduction studies (NCS), and
      is confirmed by demonstration of reduced intra-epidermal nerve fiber density (IENFD) or
      abnormal quantitative sensory testing (QST). Despite intensive search for underlying causes
      such as diabetes mellitus, impaired glucose tolerance, Fabry's disease, hereditary disorders,
      celiac disease, sarcoidosis, HIV and other systemic illnesses which may be potentially
      treatable, the proportion of patients with idiopathic SFN (I-SFN) remains substantial,
      ranging in different series from 24% up to 93%. It is conceivable that immunological
      mechanisms play a role in patients with I-SFN, since several immune-mediated diseases, such
      as sarcoidosis, Sjogren's disease and systemic lupus erythematosis may cause SFN.
      Auto-antibodies have also been reported in patients with SFN. Moreover, inflammatory changes
      in nerves have been found. Elevated pro-inflammatory cytokines have been suggested to be
      involved in the pathophysiology of pain in SFN.

      In other immune-mediated neuropathies, such as chronic inflammatory demyelinating
      polyneuropathy, treatment with intravenous immunoglobulin (IVIg) has proven to be
      efficacious. Moreover, some case studies in patients with SFN and chronic pain have also
      reported effect of immunomodulating therapy. Pain reduction with IVIg treatment has also been
      summarized recently.

      Intravenous infusion of high doses of pooled immunoglobulin G (IgG) molecules from thousands
      of donors (IVIg therapy) represents an efficient anti-inflammatory treatment for many
      autoimmune diseases. Paradoxically, IgG can exert both pro- and anti-inflammatory activities,
      depending upon its concentration. When administered in high concentrations, IVIg has
      anti-inflammatory properties. How this anti-inflammatory effect is mediated has not yet been
      fully elucidated. Several mutually nonexclusive mechanisms have been proposed, including
      modulation of the expression and function of the Fc fragment of IgG to IgG-specific
      receptors, interference with activation of the complement cascade and the cytokine network,
      neutralization of autoantibodies and regulation of cell proliferation. However, the exact
      mechanism of IVIg in the treatment of inflammatory neuropathies has not been elucidated.

      Side effects of IVIg treatment are usually transient (chills, headache, dizziness, fever,
      vomiting, nausea, arthralgia, low blood pressure and moderate low back pain may occur
      occasionally).

      Sudden fall in blood pressure and anaphylactic shock are rare. More severe side effect are
      extremely rare (reversible aseptic meningitis, transient cutaneous reactions, reversible
      haemolytic reactions, haemolytic anemia, and thromboembolic events).

      SFN is considered the most common cause of neuropathic pain in peripheral neuropathies.
      Patients with SFN have reported having excruciating pain, since current anti-neuropathic and
      other pain drugs do not relief pain substantially. SFN interferes with daily functioning and
      may lead to a decrement in quality of life expectations. Therefore, a better treatment is
      warranted. The aim of the current pilot study is to investigate the efficacy and safety of
      IVIg in patients with I-SFN in a randomized, double-blind, placebo-controlled study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Intensity Numerical Rating Scale (PI-NRS)</measure>
    <time_frame>Mean weekly pain intensity is assessed twice a week for a period of three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Intensity Numerical Ratings Scale (PI-NRS)</measure>
    <time_frame>The nocturnal pain intensity will be assessed twice a week for a period of three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>The global impression of change will be measured 5 times in three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Small Fiber Neuropathy Symptoms Inventory Questionnaire (SFN-SIQ)</measure>
    <time_frame>This will be measured 5 times in three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropathic Pain Scale (NPS)</measure>
    <time_frame>This will be measured 5 times in three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Small Fiber Neuropathy Rasch-Built Overall Disability Scale (SFN-RODS)</measure>
    <time_frame>This will be measured 5 times in three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief questionnaire</measure>
    <time_frame>This will be measured 5 times in three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Daily sleep interference scale (DSIS)</measure>
    <time_frame>This will be measured 5 times in three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36</measure>
    <time_frame>This will be measured 5 times in three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, laboratory safety tests, vital signs.</measure>
    <time_frame>This will be measured 8 times in three months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Small Fiber Neuropathy</condition>
  <arm_group>
    <arm_group_label>Intravenous Immunoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive intravenous immunoglobulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Saline 0.9%)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive placebo (saline 0.9%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Immunoglobulin</intervention_name>
    <description>Comparison between intravenous immunoglobulin and placebo (saline 0.9%).</description>
    <arm_group_label>Intravenous Immunoglobulin</arm_group_label>
    <other_name>Gamunex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.</description>
    <arm_group_label>Placebo (Saline 0.9%)</arm_group_label>
    <other_name>Saline (0.9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients can only participate when they are living in the Netherlands.

        Inclusion Criteria:

          -  18 years or older.

          -  Skin-biopsy proven idiopathic SFN or idiopathic painful neuropathy with predominantly
             SFN pattern

          -  Pain intensity rated â‰¥ 5 on the PI-NRS (maximum pain) or on the neuropathic pain
             scale,36,37 question number 1 for at least 12 weeks before the study as declared by
             each patient to the best of their knowledge; if available, medical records of each
             patient will be consulted on the reported pain intensity.

          -  Each subject will receive an information leaflet and an informed consent form.
             Subjects must give informed consent by signing and dating prior to study entry.

          -  Eligible patients must be willing to complete all study-related activities and
             examination required by the protocol (see Tables 1-4).

        Exclusion Criteria:

          -  Are unable or unwilling to provide written informed consent.

          -  Have predominant clinical picture of large nerve fiber involvement (i.e., weakness,
             loss of vibration sense, hypo-/areflexia).

          -  Had treatment with IVIg or any other immunomodulatory/immunosuppressive agents (e.g.,
             steroids) within the last 12 weeks prior to the date of informed consent.

          -  Have an underlying cause of SFN (diabetes, SCN9A/10A/11A mutations, hypothyroidism,
             renal failure, vitamin B12 deficiency, monoclonal gammopathy, alcohol abuse (more than
             5 IU/day), malignancies, drugs that cause neuropathy (e.g. chemotherapy, amiodarone,
             propafenone)).

          -  Have a history of anaphylaxis or severe systemic response to immunoglobulin or with a
             blood product.

          -  Have cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac
             dysrhythmia requiring treatment, unstable or advanced ischemic heart disease, or
             history of congestive heart failure, severe hypertension (diastolic blood pressure
             &gt;120 mmHg or systolic &gt;170 mmHg).

          -  Are females who are pregnant, breast-feeding, or if of childbearing potential, or
             unwilling to practice adequate contraception throughout the study.

          -  Have known hyperviscosity.

          -  Have a history of renal insufficiency or high serum creatinine levels (MDRD &lt;30).

          -  Have known selective immunoglobulin A (IgA) deficiency.

          -  Have conditions whose symptoms and effects could alter protein catabolism and/or IgG
             utilization (e.g. protein-losing enteropathies, nephrotic syndrome).

          -  Have a known hypercoagulable state.

          -  Are mentally challenged adult subjects unable to give independent informed consent.

          -  The use of pain (analgesic/anti-neuropathic) medication is allowed, but only if
             dosages are remained unchanged for at least 30 days prior to randomization. A change
             in dosage of these drugs will not be allowed throughout the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catharina G Faber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Ziekenhuis Maastricht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catharina G Faber, MD, PhD</last_name>
    <phone>+31433877059</phone>
    <email>c.faber@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catharina G Faber, MD, PhD</last_name>
      <phone>+31433877059</phone>
      <email>c.faber@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Ziekenhuis Maastricht</investigator_affiliation>
    <investigator_full_name>Catharina G. Faber</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Small Fiber Neuropathy</keyword>
  <keyword>Painful Neuropathy</keyword>
  <keyword>Intravenous Immunoglobulin Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Small Fiber Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

